<DOC>
	<DOCNO>NCT01993524</DOCNO>
	<brief_summary>The purpose study determine whether supplementation standard antibiotic therapy oral probiotic preparation prOVag contain lactic acid bacteria influence recurrence bacterial vaginosis/vaginitis .</brief_summary>
	<brief_title>Supplementation Standard Antibiotic Therapy With Oral Probiotics Bacterial Vaginosis</brief_title>
	<detailed_description>Bacterial vaginosis common vaginal infection woman reproductive age . This condition cause overgrowth anaerobic bacteria concomitant reduction Lactobacillus population vagina , i.e . disruption vaginal microbiota . Aerobic vaginitis relate suppression lactobacilli various aerobic bacteria , mostly originate anal microbiota . Previous open-label study confirm probiotic strain - Lactobacillus fermentum 57A , Lactobacillus plantarum 57B , Lactobacillus gasseri 57C give orally woman intermediate/abnormal vaginal flora clinical symptom ability colonize rectum vagina contribute maintenance pH level Nugent score . The colonisation woman test strain confirm microbiological molecular method . The purpose multicentre , randomize study investigate whether use probiotic preparation contain Lactobacillus fermentum 57A , Lactobacillus plantarum 57B , Lactobacillus gasseri 57C together standard treatment bacterial vaginosis/vaginitis could reduce recurrence rate condition , assess use clinical microbiological criterion , comparison standard treatment alone . The study take place March 2009 February 2012 nine private out-patient gynaecological clinic Krakow area Katowice ( Silesia ) Poland . It conduct accordance original protocol accord ICH-GCP requirement . The duration subject 's participation trial approximately 5-6 month ( follow-up visit include ) . As trial concern medicinal product foodstuff ( dietary supplement ) require Authority approval subject relevant Ethics Committee approval . Women history recurrent bacterial vaginosis/vaginitis , age 18 - 50 year , comply inclusion exclusion criterion sign informed consent form enrol randomized one study group . Efficacy parameter base evaluation clinical symptom gynaecological examination , well determination vaginal pH , Nugent score , total Lactobacillus count presence/numbers vaginal pathogen culture vaginal swab collect visit . Data obtain third-fifth visit compare obtain first visit . Clinical sample transport central laboratory analysis . Safety parameter analyse use information record 'patient 's diary ' throughout study period , well investigator 's assessment visit .</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Vaginitis</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<criteria>1 . Informed Consent Form 2 . Subjects age equal 18 less equal 50 year 3 . Women Caucasian race 4 . Regularly menstruate premenopausal woman ( normal menstrual function ( Eumenorrhoea ) shall mean regular menstrual bleeding pattern every 28 plus/minus 10 day ) 5 . No irregularity identify gynaecological examination ( pathology reproductive organ , myoma , ovarian cyst ) 6 . Susceptibility recurrent vaginitis and/or urinary tract infection , well bacterial vaginitis confirm visit I 1 . Subjects age less 18 50 year 2 . Hypersensitivity ingredient investigational product , metronidazole antibiotic ( ) . 3 . Bleeding genital tract unknown aetiology 4 . Pregnancy 5 . Breastfeeding 6 . Congenital acquire immunodeficiency 7 . Diabetes 8 . Mental illness 9 . Neoplastic disease 10 . Application mechanical contraceptive , : diaphragm , intrauterine contraceptive insert ( except Mirena intrauterine device ) 11 . Application NuvaRing hormonal contraceptive vaginal ring 12 . Application hormonal preparation , : Vagifem , Ovestin vaginal estrogen reproductive period 13 . Application another oral and/or vaginal probiotic Subject qualification Study 14 . Participation another clinical study / le thirtyday interval last clinical study 15 . Mycotic vaginitis 16 . Antibiotic therapy reason 17 . Pathology reproductive organ ( myoma , ovarian cyst , etc . ) 18 . Scheduled surgery hospitalization</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>